12 — Dysbiosis (dysbiosis)
"Integrative" hallmark added in the update by López-Otín et al., Cell 2023 (10.1016/j.cell.2022.11.001). It concerns the imbalance of the gut microbiota with age and its effects on the whole organism.
1. Definition
The gut microbiota is the set of billions of bacteria, viruses and fungi that live in our intestine. With age, its composition becomes unbalanced: fewer beneficial bacteria, more pro-inflammatory bacteria, and diversity that is often reduced in frail people. This imbalance is called dysbiosis.
In plain terms: the gut is home to a "garden" of microbes that helps us digest, defend ourselves and make useful molecules. With age, the weeds gain ground and the garden produces fewer good things.
2. Mechanisms and sources
- Loss of diversity linked to lifestyle: in older Irish people, the composition of the microbiota follows where they live and what they eat. Residents of care homes, with a less varied diet, have a less diverse microbiota, associated with more frailty and inflammation (Claesson 2012, 10.1038/nature11319).
- Healthy aging has a signature: in more than 9,000 people, the microbiota becomes increasingly "unique" (moves away from the average profile) with age in healthy people, and this pattern predicts survival; it is absent in people in poorer health (Wilmanski 2021, 10.1038/s42255-021-00348-0).
- Leaky gut and inflammation: in mice, age-related dysbiosis increases intestinal permeability. Bacterial products pass into the blood and trigger systemic inflammation; germ-free mice do not show this rise in inflammation with age (Thevaranjan 2017, 10.1016/j.chom.2017.03.002).
- Harmful metabolites: some bacteria convert choline and carnitine (red meat, eggs) into TMA, which the liver turns into TMAO, which promotes atherosclerosis in mice (Wang 2011, 10.1038/nature09922). In humans, high TMAO is associated with more cardiovascular events (Tang 2013, 10.1056/NEJMoa1109400).
- Protective metabolites: Japanese centenarians have a microbiota enriched in pathways producing particular bile acids (such as isoallo-lithocholic acid) that inhibit pathogenic bacteria (Sato 2021, 10.1038/s41586-021-03832-5). Short-chain fatty acids (butyrate), produced from fibre, feed the intestinal wall and calm inflammation (review: Ghosh 2022, 10.1038/s41575-022-00605-x).
- Aggravating factors: medicines (antibiotics, proton pump inhibitors), polypharmacy, loss of appetite, low-fibre diet, sedentary lifestyle.
3. Symptoms and clinical manifestations
- Frailty and muscle loss: associated with a depleted microbiota (Claesson 2012).
- Chronic inflammation and infections: higher risk of Clostridioides difficile infection in older people.
- Cardiovascular disease: via TMAO (Tang 2013).
- Metabolic disease: type 2 diabetes, obesity.
- Cognitive decline: gut-brain axis, mostly shown in mice (Parker 2022, 10.1186/s40168-022-01243-w).
- What centenarians show: their microbiota is enriched in bacteria considered beneficial (Akkermansia, Bifidobacterium, Christensenellaceae) (Biagi 2016, 10.1016/j.cub.2016.04.016).
- Major limitation: in humans, almost all data are correlations. It is not always known whether dysbiosis causes poor aging or results from it (diseases, medicines, diet).
4. Interactions with the other hallmarks
- Genomic instability (01): some bacterial toxins damage the DNA of intestinal cells (link mostly established for colorectal cancer).
- Telomere attrition (02) and epigenetic alterations (03): bacterial metabolites (butyrate, folates) influence the host's epigenetic marks.
- Loss of proteostasis (04) and disabled macroautophagy (05): urolithin A, produced by bacteria from ellagitannins (pomegranate, walnuts), activates mitophagy (recycling of mitochondria) (Ryu 2016, 10.1038/nm.4132).
- Deregulated nutrient sensing (06): the microbiota modulates the response to diet and to metformin (Wu 2017, 10.1038/nm.4345).
- Mitochondrial dysfunction (07): see urolithin A.
- Cellular senescence (08): inflammation of intestinal origin promotes senescence.
- Stem cell exhaustion (09): the microbiota influences the renewal of the intestinal wall.
- Altered intercellular communication (10): bacterial metabolites are circulating messengers (gut-brain and gut-heart axes).
- Chronic inflammation (11): the strongest link; intestinal permeability fuels inflammaging (Thevaranjan 2017).
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Fecal microbiota transplant (FMT) young → old | Whole microbiota | Preclinical (killifish) | Longer lifespan | Smith 2017 |
| FMT in progeroid mice | Microbiota, Akkermansia | Preclinical (mice) | Longer healthspan and lifespan | Bárcena 2019 |
| FMT young → old | Gut, eye, brain | Preclinical (mice) | Reversal of markers of intestinal, retinal and brain aging | Parker 2022 |
| Mediterranean diet for 1 year (NU-AGE) | Microbiota composition | Randomised human trial (>600 older people) | Bacteria associated with less frailty, better cognition, less inflammation | Ghosh 2020 |
| Fermented foods (10 weeks) | Microbial diversity | Randomised human trial (n=36) | Higher diversity, lower inflammatory markers | Wastyk 2021 |
| Pasteurised Akkermansia muciniphila | Metabolism | Human pilot trial (n=32, overweight) | Better insulin sensitivity, safe | Depommier 2019 |
| Urolithin A | Mitophagy | Human phase I and II trials | Safe; improved muscle endurance in older people (primary walking endpoint not met) | Andreux 2019 ; Liu 2022 |
| Metformin via the microbiota | Bacterial metabolism | Preclinical (worm); human observational | Extends worm life by altering its bacteria; part of the antidiabetic effect goes through the microbiota | Cabreiro 2013 ; Wu 2017 |
| FMT for recurrent C. difficile | Infection | Randomised human trial; approved (infectious indication, not anti-aging) | 81% cure after one infusion vs 31% with vancomycin alone | van Nood 2013 |
No microbiota intervention is approved to slow aging.
In plain terms: eating a varied diet rich in fibre and fermented foods is the best-supported lead in humans, even though effects on lifespan remain unproven.
6. Open questions
- Cause or consequence? In humans, is dysbiosis a driver of aging or a reflection of disease, medicines and diet?
- What is a "good" old-age microbiota? It varies by country, diet and individual. There is no consensus definition.
- FMT in older humans: safety (transmission of pathogens) and durability of the effect remain to be established outside the infectious indication.
- Probiotics: most commercial strains have no proven effect on aging; effects depend on the strain and the person.
- Molecular mechanisms: which specific metabolites (bile acids, butyrate, urolithin A, TMAO) carry most of the effect?
7. References
- López-Otín C. et al. (2023) Hallmarks of aging: An expanding universe. Cell. 10.1016/j.cell.2022.11.001
- Ghosh T.S., Shanahan F., O'Toole P.W. (2022) The gut microbiome as a modulator of healthy ageing. Nature Reviews Gastroenterology & Hepatology. 10.1038/s41575-022-00605-x
- Claesson M.J. et al. (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature. 10.1038/nature11319
- Biagi E. et al. (2016) Gut microbiota and extreme longevity. Current Biology. 10.1016/j.cub.2016.04.016
- Wilmanski T. et al. (2021) Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nature Metabolism. 10.1038/s42255-021-00348-0
- Thevaranjan N. et al. (2017) Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host & Microbe. 10.1016/j.chom.2017.03.002
- Sato Y. et al. (2021) Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 10.1038/s41586-021-03832-5
- Wang Z. et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 10.1038/nature09922
- Tang W.H.W. et al. (2013) Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. NEJM. 10.1056/NEJMoa1109400
- Smith P. et al. (2017) Regulation of life span by the gut microbiota in the short-lived African turquoise killifish. eLife. 10.7554/eLife.27014
- Bárcena C. et al. (2019) Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nature Medicine. 10.1038/s41591-019-0504-5
- Parker A. et al. (2022) Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain. Microbiome. 10.1186/s40168-022-01243-w
- Ghosh T.S. et al. (2020) Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 10.1136/gutjnl-2019-319654
- Wastyk H.C. et al. (2021) Gut-microbiota-targeted diets modulate human immune status. Cell. 10.1016/j.cell.2021.06.019
- Depommier C. et al. (2019) Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 10.1038/s41591-019-0495-2
- Ryu D. et al. (2016) Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 10.1038/nm.4132
- Andreux P.A. et al. (2019) The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 10.1038/s42255-019-0073-4
- Liu S. et al. (2022) Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Network Open. 10.1001/jamanetworkopen.2021.44279
- van Nood E. et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM. 10.1056/NEJMoa1205037
- Cabreiro F. et al. (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 10.1016/j.cell.2013.02.035
- Wu H. et al. (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine. 10.1038/nm.4345